Shi et al. [17] found that aberrant methylation in the DBC2 promoter may be responsible for the loss of DBC2 expression in bladder cancer and this hypermethylation event could play a crucial role in the early stage of bladder tumorigenesis. This evidence concerns the gene RHOBTB2 and urogenital neoplasm.